Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + vincristine + apatinib for relapsed/refractory adult rhabdomyosarcoma
ChiCTR2500097888Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, vincristine and Rivoceranib in rhabdomyosarcoma (RMS), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Progression-free survival and Safety. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
irinotecan liposomevincristineRivoceranib
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on ChiCTR2500097888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097888.